

1 **Incidence and Risk Factors of Second Primary**
2 **Cancer after the Initial Primary Human**
3 **Papillomavirus Related Neoplasms**

4

5 Jiayi Shen^{1,2#}, Huaqiang Zhou^{1,2,#}, Jiaqing Liu^{1,2}, Zhonghan Zhang¹, Wenfeng Fang¹, Yunpeng Yang¹,

6 Shaodong Hong¹, Yuxiang Ma³, Ting Zhou¹, Yaxiong Zhang¹, Hongyun Zhao¹, Yan Huang^{1,*}, Li Zhang^{1,*}

7

8 ¹ Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of
9 Oncology in South China, Collaborative Innovation Center for Cancer Medicine;

10 ² Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China;

11 ³ Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of
12 Oncology in South China, Collaborative Innovation Center for Cancer Medicine.

13 # These authors contributed equally to this work.

14

15 Corresponding Author:

16 Yan Huang and Li Zhang

17 Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng
18 Road East, Guangzhou, Guangdong 510060, China

19 Email address: huangyan@sysucc.org.cn; zhangli6@mail.sysu.edu.cn

20

21

22

23 **Abstract**

24 **Background:** Human papillomavirus (HPV)-related cancers are nowadays associated with
25 better survival. However, comprehensive studies in second primary cancer (SPC) after the
26 initial primary HPV-related cancer still remain warranted. Therefore, this study was designed
27 to analyse the incidence and risk factors of SPC after HPV-related cancer.

28 **Methods:** We identified 86,790 patients diagnosed with initial primary HPV-related cancer
29 between 1973 and 2010 in the National Cancer Institute's Surveillance, Epidemiology, and
30 End Results (SEER) 9 database. Standardized incidence ratio (SIR) and cumulative incidence
31 were calculated to assess the risk of SPC after HPV-related cancer. Subdistribution hazard
32 regression was also conducted to figure out the risk factors.

33 **Results:** SIR of SPC after HPV-related cancer was 1.60 (95% confidence interval [CI]
34 1.55-1.65) for male and 1.25 (95% CI 1.22-1.28) for female. SIR of second primary
35 HPV-related cancer (7.39 [95% CI 6.26-8.68] male and 4.35 [95% CI 4.04-4.67] female) was
36 obviously higher than that of second primary HPV-unrelated cancer (1.54 [95% CI 1.49-1.60]
37 male and 1.16 [95% CI 1.13-1.19] female). 5-year cumulative incidence of SPC was 7.22%
38 (95% CI 6.89%-7.55%) for male and 3.72% (95% CI 3.58%-3.88%) for female. Risk factors
39 of SPC included being married and initial primary cancer (IPC) diagnosed at earlier stage for
40 both gender, and IPC diagnosed at older age as well as surgery performed for female only.

41 **Conclusion:** Patients diagnosed with HPV-related cancer are more likely to develop another
42 primary cancer, as compared with the age-specific reference population. Patients with the risk
43 factors claimed in this study are suggested to screen for SPC regularly. According to the

44 elevation of SIR of HPV-related SPC, it is suggested that part of the HPV-related SPC cases

45 may be caused by the persistent infection of HPV.

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66 **Introduction**

67 HPV infection is a common viral infection, with its relatively high prevalence (11% in oral
68 cavity, 26.8% for female in genital organs, 14% for female in anus, 45.2% for male in genital
69 organs and 16% for male in anus).¹⁻⁵ Many types of HPV have been classified as Group 1
70 carcinogen by the International Agency for Research on Cancer (IARC). HPV is a carcinogen
71 in some cancers, with base of tongue, tonsillar, oropharyngeal, Waldeyer's ring, anal, vulvar,
72 vaginal, cervical and penile cancers included.⁶⁻⁹ We grouped cancers listed above as
73 HPV-related cancer and the rest as HPV-unrelated cancer. According to the study by de
74 Martel et al., HPV infection is responsible for 4.5% (630,000 new cases per year) of all cancer
75 cases worldwide. The attributable fraction ranges from < 3% to > 20% in different regions.¹⁰
76 Despite the burden of HPV-related cancer, we have seen the improvement in the prognosis of
77 HPV-related cancer, due to the more advanced treatment and earlier detection.¹¹⁻¹⁶ Improved
78 survival from the IPC means the elevated risk of SPC.¹⁷ The investigation into SPC after
79 HPV-related cancer is urgent, based on the high prevalence of HPV-related cancer and the
80 improved survival.

81 There have been some reports about incidence of SPC after some of the HPV-related
82 cancers. SIR after oral, oropharyngeal, anal and cervical cancer was 2.82, 2.99, 1.41 and 1.56
83 respectively.¹⁸⁻²⁰ However, in the light of the strong carcinogenic effect of HPV, HPV-related
84 cancer should be classified as a whole when considering SPC, to observe whether there will
85 be some special patterns of the occurrence of SPC. Hereby, we aimed to analyse the incidence
86 and risk factors of SPC after initial primary HPV-related cancer.

87

88 **Materials and Methods**

89 SEER program has been collecting demographic and clinical characteristics and follow up
90 of cancer patients in America since 1973, with its registries covering approximately 34.6
91 percent of the U.S. population currently. In this study, we acquired data from SEER 9, a
92 database in SEER*Stat software version 8.3.5 containing information of cancer patients from
93 9 different registers.

94 Patient cohort to be observed in this study included those who were diagnosed to have
95 HPV-related cancer as their IPC between 1973 and 2010. IPC was defined as the first record
96 of primary malignant tumor in SEER system. HPV-related cancer included cancer in base of
97 tongue (C01.9), tonsillar cancer (C02.4, C09), oropharyngeal cancer (C10), Waldeyer's ring
98 cancer (C14.2), anal canal cancer (C21), vulvar cancer (C51), vaginal cancer (C52.9), cervical
99 cancer (C53), and penile cancer (C60).⁶⁻⁹ Those diagnosed with HPV-related cancer when
100 aged less than 18 years old were not involved in this study. Records with death certificate or
101 autopsy only were excluded. Finally, 86,790 patients diagnosed with initial primary
102 HPV-related cancer were included.

103 SPC was defined as the second primary malignant tumor records in SEER system diagnosed
104 between January 1973 and December 2015 and with a latency over or equal to 6 months.²¹
105 The year of 2010 and 2015 were selected as the last years for the diagnosis of initial primary
106 HPV-related cancer and SPC, respectively, to ensure that all patients included were followed
107 up for at least 5 years.

108 SIR of SPC is defined as observed number of SPC cases in the study cohort divided by
109 expected number of cases computed using age-specific rates from a reference population,

110 weighted according to the age structure of the study population.²² The calculation of SIR was
111 done via the MP-SIR session in SEER software. SIR of SPC after the diagnosed of
112 HPV-related cancer and HPV-unrelated cancer were calculated.

113 In this study, death is regarded as the competing event with SPC. Cumulative incidence
114 analysis was completed under the consideration of competing risk. To figure out the risk
115 factors of SPC after the initial primary HPV-related cancer, we conducted the multivariable
116 subdistribution hazard regression, regarding death as the competing event with SPC.²³ Age,
117 race, marital status, TNM stage and surgery were considered to be potential risk factors of
118 SPC. When conducting subdistribution hazard regression, patient cohort merely included
119 those who were diagnosed to have HPV-related cancer as their IPC between 2004 and 2010,
120 for the reason that TNM stage (6th edition) is only available since 2004. Correspondingly,
121 SPC were defined as SPC records in SEER system diagnosed between January 2004 and
122 December 2015.

123 All the results were presented by gender, except when the IPC was genital cancer, to avoid
124 unexpected bias. Both the cumulative incidence analysis and the subdistribution hazard
125 regression were performed using R version 3.5.0 (Institute for Statistics and Mathematics,
126 Vienna, Austria; www.r-project.org). Statistical significance was set at two-sided $P < 0.05$.

127

128 **Results**

129 *Incidence of SPC*

130 The SIR of SPC after HPV-related cancer was 1.60 (95% CI 1.55-1.65) for male and 1.25
131 (95% CI 1.22-1.28) for female. (Figure 1) Moreover, SIR of second primary HPV-related
132 cancer (7.39 [95% CI 6.26-8.68] male and 4.35 [95% CI 4.04-4.67] female) was obviously

133 higher than that of second primary HPV-unrelated cancer (1.54 [95% CI 1.49-1.60] male and
134 1.16 [95% CI 1.13-1.19] female). When SPC site was limited to every single HPV-related site,
135 the consistent elevation of SIR was observed. However, notably, for female patients, SIR of
136 SPC in cervix uteri (1.10 [95% CI 0.89-1.34]) was similar to that of SPC in all sites (1.25 [95%
137 CI 1.22-1.28]). There has been insufficient evidence for the role of HPV in several cancers,
138 which were considered as potentially HPV-related cancer in this study, with esophagus,
139 larynx, nose and nasal sinus, lung, colon and rectum, breast, prostate and urinary bladder
140 included.²⁴⁻³¹ We also observed an increase in SIR of SPC among some of the potentially
141 HPV-related sites, with esophagus (4.16 [95% CI 3.49-4.93] male and 2.88 [95% CI
142 2.34-3.51] female), larynx (3.21 [95% CI 2.59-3.94] male and 3.00 [95% CI 2.31-3.82]
143 female), nose and nasal sinus (4.36 [95% CI 2.39-7.32] for male only), lung and bronchus
144 (2.66 [95% CI 2.48-2.84] male and 2.08 [95% CI 1.98-2.18] female), trachea (8.42 [95% CI
145 1.74-24.61] male and 6.48 [95% CI 2.11-15.13] female) and urinary bladder (1.96 [95% CI
146 1.74-2.20 for female only) included.

147 HPV-related head and neck cancer contributed more to the SIR of SPC after HPV-related
148 cancer than HPV-related anogenital cancer. (Table 1) In addition, how SIR was affected by
149 SPC sites when IPC was limited to every single HPV-related cancer was also provided.

150 (Table S1-6)

151 SIR of SPC after HPV-unrelated cancer (0.88 [95% CI 0.88-0.89] male and 1.12 [95% CI
152 1.11-1.12] female) was lower when compared with that of SPC after HPV-related cancer
153 (1.60 [95% CI 1.55-1.65] male and 1.25 [95% CI 1.22-1.28] female). (Figure 2)

154 The temporal pattern of SIR was apparent. SIR would be raised, if the IPC was diagnosed in
155 more recent years. (Figure 3) The 1-year, 3-year, 5-year and 10-year cumulative incidence of
156 SPC was 1.19% (95% CI 1.06%-1.33%) for male and 0.63% (95% CI 0.57%-0.69%) for
157 female, 4.78% for male (95% CI 4.51%-5.06%) and 2.33% (95% CI 2.22%-2.45%) for
158 female, 7.22% (95% CI 6.89%-7.55%) for male and 3.72% (95% CI 3.58%-3.88%) for
159 female and 11.98% (95% CI 11.56%-12.42%) for male and 6.87% (95% CI 6.67%-7.08%)
160 for female, respectively.

161

162 ***Risk factors of SPC***

163 Marital status and TNM stage were significantly associated with SPC for both genders.
164 (Table 2) Age and surgery were also significant predictive factors of SPC for female patients.

165 According to the result of subdistribution hazard regression, older female patient (with their
166 IPC diagnosed when aged over 65 years old) (sdHR=1.50, [95% CI 1.28 - 1.76], P<0.001)
167 were at more risk for SPC. As compared with married patients, those unmarried got a lower
168 risk of developing SPC, with the sdHR of 0.74 (95% CI 0.63 - 0.86, P<0.001) for male and
169 0.77 (95% CI 0.66 - 0.90, P<0.001) for female, respectively. In this study, those variables
170 related to poor prognosis, including later TNM stage for both gender and surgery not
171 performed for female, were also protective factors for SPC.

172

173 **Discussion**

174 In this study, we estimated the risk and risk factors of SPC after the initial primary
175 HPV-related cancer. The SIR of SPC was 1.60 (95% CI 1.55-1.65) for male and 1.25 (95% CI

176 1.22-1.28) for female. The SIR, which was larger than 1, indicated that patients diagnosed
177 with HPV-related cancer are more likely to develop another primary cancer, as compared with
178 the age-specific reference population. Patients with the risk factors claimed in the competing
179 risk analysis are suggested to screen for SPC regularly.

180 The elevation of SIR (>1) can partially be explained by their persistent carcinogenic
181 lifestyle like smoking and alcohol consumption.^{32,33} In addition, patients once diagnosed with
182 HPV-related cancer may be also those who were genetically susceptible to cancer, thus being
183 more likely to develop another primary cancer than the corresponding reference population.³⁴
184 If those two hypotheses mentioned above were the only two explanations of SPC after
185 HPV-related cancer, we would have seen the similar SIR of different SPC sites, because the
186 carcinogenic effect of both the carcinogenic lifestyle and being genetically susceptible to
187 cancer exists in most of cancers. However, we actually observed the elevation of SIR of SPC
188 in HPV-related sites and this result is also supported by Neumann et al.³⁵ Moreover,
189 considering the strong carcinogenic effect of HPV in the HPV-related sites⁶⁻⁹, it is suggested
190 that part of the HPV-related SPC cases may be caused by the persistent infection of HPV.

191 HPV can be transmitted from the primary infected site to the later infected sites. To be
192 specific, HPV virus can circulate to infect other organs, with HPV DNA and mRNA detected
193 in peripheral blood of cervical cancer patients.^{36,37} Another theory for the transmission of
194 HPV from anus, cervix uteri and other genital organs to oral cavity, oropharynx and tonsil and
195 then causing SPC is that HPV was transmitted in the process of oral sex or by touching the
196 mouth with contaminated hands. Moreover, another primary cancer in the same site as that in
197 IPC may also occur under the effect of HPV, after the elimination of tumor cells of IPC. Next,

198 in those organs infected later, the similar carcinogenic process of HPV with that in IPC occurs.

199 Considering the carcinogenic effect of HPV in both the IPC and its potential carcinogenic
200 effect in second primary HPV-related cancer, HPV vaccine is promoted for the prevention,
201 based on the benefit of HPV vaccination claimed by Nicol et al.³⁸

202 We observed the elevation of SIR in some of the potentially HPV-related SPC sites
203 including esophagus, larynx, nose and nasal sinus (for male only), lung and bronchus, trachea
204 and urinary bladder (for female only). According to the hypothesis that the infection of HPV
205 may be a reason for the occurrence of SPC, we think this can be an indirect evidence for the
206 carcinogenicity of HPV in these potentially HPV-related sites, of which SIR was elevated.

207 For instance, as was promoted by Xiong WM et al., HPV can be transmitted to and infect lung
208 by blood circulation, through the air or by high-risk sexual behavior, through which HPV was
209 transmitted to mouth, throat and then lung.³⁹ Then, HPV performs its carcinogenicity, causing
210 second primary lung cancer.^{36, 37} And this is also an indication for the necessity of further
211 exploration of the carcinogenic effect of HPV in esophagus, larynx, nose and nasal sinus, lung
212 and bronchus, trachea and urinary bladder.

213 The SIR of SPC after HPV-unrelated cancer is lower than 1 for male. But this can not be the
214 evidence of that HPV-unrelated cancer is a protective factor for the development of another
215 primary cancer in male, because there have been many reports of SIR after HPV-unrelated
216 cancers like hepatocellular cancer(10.07), stage Ia non-small-cell lung cancer(2.07), gastric
217 cancer (1.11) and osteosarcoma (1.60), which was significantly larger than 1.^{21, 40-42} However,
218 this can be an indication that there might be survivors from some specific cancers who may be
219 less likely to develop another primary cancer when compared with the corresponding

220 population due to the poor prognosis or so on, which needs further investigation. For example,
221 SIR of SPC after the initial primary gastroenteropancreatic neuroendocrine tumors was
222 reported to be 0.72.⁴³

223 We also saw the increase of SIR by attained calendar year, which means a growing
224 necessity of screening for SPC nowadays. Our results were same to those by Suk et al.⁴⁴ We
225 assumed that the possible reason for the increase may be the improvement of survival from
226 many of the HPV-related cancers in recent years and the arising and popularization of the
227 more effective detection approaches.^{11-16, 45, 46} The improvement of survival reduced the
228 competing effect of death with SPC, while the more effective detection approach made the
229 detection of some cases possible.

230 According to the result of the subdistribution hazard regression, some prognostic indicators
231 of IPC were also indicators for the occurrence of SPC, with TNM stage (for both gender) and
232 surgery (for female only) included. Further, indicators of better survival of IPC also implied a
233 larger chance of developing SPC, which was supported by the Grundmann et al.¹⁷

234 There are also some limitations in our study. First of all, although we believe in the quality
235 of records in SEER system, there may be some incorrect records of SPC in SEER, for the
236 natural difficulty in distinguishing SPC from tumor metastasis and recurrence. Second,
237 information about infection of HPV and lifestyle of patients like smoking and alcohol
238 consumption is not available in SEER database. Because of the lack of information about
239 HPV-positivity status, HPV-relatedness was by proxy in this study.

240

241 **Conclusions**

242 This study is of clinical significance and can help promote public health. According to our
243 results, considering the persistent carcinogenesis of HPV and the SIR of SPC increasing by
244 year, patients once diagnosed with HPV-related cancer should screen for SPC regularly,
245 especially when they get a high predictive risk for SPC according to the result of our
246 subdistribution hazard regression.

247

248 **Acknowledgments**

249 The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results
250 (SEER) Program tumor registries in providing high quality open resources for researchers.
251 The authors would like to thank the editors and the anonymous reviewer for their valuable
252 comments and suggestions to improve the quality of the paper.

253

254 **References**

- 255 1. Candotto V, Lauritano D, Nardone M, et al. HPV infection in the oral cavity: epidemiology, clinical
256 manifestations and relationship with oral cancer. *Oral Implantol.* 2017;10: 209-220.
- 257 2. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United
258 States. *JAMA.* 2007;297: 813-819.
- 259 3. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its
260 relationship with cervical infection. *Cancer Epidemiol. Biomarkers Prev.* 2005;14: 2550-2556.
- 261 4. Han JJ, Beltran TH, Song JW, Klaric J, Choi YS. Prevalence of Genital Human Papillomavirus
262 Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and
263 Nutrition Examination Survey (NHANES) 2013-2014. *JAMA Oncol.* 2017;3: 810-816.
- 264 5. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for
265 anal human papillomavirus (HPV) among men who have sex with women and men who have sex with
266 men: the HPV in men (HIM) study. *J. Infect. Dis.* 2011;203: 49-57.
- 267 6. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus
268 prevalence in invasive penile cancer. *Cancer Causes Control.* 2009;20: 449-457.
- 269 7. Vuyst HD, De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and
270 type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina
271 and anus: A meta-analysis. *International Journal of Cancer.* 2009;124: 1626-1636.
- 272 8. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of
273 invasive cervical cancer worldwide. *J. Pathol.* 1999;189: 12-19.
- 274 9. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human
275 papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *J. Clin.*

- 276 Oncol. 2008;26: 612-619.
- 277 10. Martel Cd, de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer
278 attributable to HPV by site, country and HPV type. *International Journal of Cancer*. 2017;141: 664-670.
- 279 11. Akhtar-Danesh N, Elit L, Lytwyn A. Temporal Trends in the Relative Survival Among Women With
280 Cervical Cancer in Canada: A Population-Based Study. *International Journal of Gynecologic Cancer*.
281 2012;22: 1208-1213.
- 282 12. Arya M, Li R, Pegler K, et al. Long-term trends in incidence, survival and mortality of primary penile
283 cancer in England. *Cancer Causes Control*. 2013;24: 2169-2176.
- 284 13. Chen AY, Zhu J, Fedewa S. Temporal trends in oropharyngeal cancer treatment and survival:
285 1998–2009. *The Laryngoscope*. 2014;124: 131-138.
- 286 14. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and
287 survival: the surveillance, epidemiology, and end results experience, 1973-2000. *Cancer*. 2004;101:
288 281-288.
- 289 15. Lai J, Elleray R, Nordin A, et al. Vulval cancer incidence, mortality and survival in England:
290 age-related trends. *BJOG*. 2014;121: 728-738; discussion 739.
- 291 16. Pulte D, Brenner H. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st
292 Century: A Period Analysis. *The Oncologist*. 2010;15: 994-1001.
- 293 17. Grundmann RT, Meyer F. [Second primary malignancy among cancer survivors - epidemiology,
294 prognosis and clinical relevance]. *Zentralbl. Chir*. 2012;137: 565-574.
- 295 18. Morris LGT, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head
296 and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal
297 cancer. *J. Clin. Oncol*. 2011;29: 739-746.

- 298 19. Shah BK, Budhathoki N. Second primary malignancies in anal carcinoma. *Journal of Clinical*
299 *Oncology*. 2015;33: 534-534.
- 300 20. Teng C-J, Huon L-K, Hu Y-W, et al. Secondary Primary Malignancy Risk in Patients With Cervical
301 Cancer in Taiwan. *Medicine*. 2015;94: e1803.
- 302 21. Shah BK, Kandel P, Khanal A. Second Primary Malignancies in Hepatocellular Cancer - A US
303 Population-based Study. *Anticancer Res*. 2016;36: 3511-3514.
- 304 22. Schoenberg BS, Myers MH. Statistical methods for studying multiple primary malignant neoplasms.
305 *Cancer*. 1977;40: 1892-1898.
- 306 23. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J. Am.*
307 *Stat. Assoc*. 1999;94: 496-509.
- 308 24. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck
309 squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol. Biomarkers Prev*.
310 2005;14: 467-475.
- 311 25. Lu XM, Monnier-Benoit S, Mo LZ, et al. Human papillomavirus in esophageal squamous cell
312 carcinoma of the high-risk Kazakh ethnic group in Xinjiang, China. *European Journal of Surgical*
313 *Oncology (EJSO)*. 2008;34: 765-770.
- 314 26. El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing
315 (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease
316 entity. *Am. J. Surg. Pathol*. 2005;29: 1367-1372.
- 317 27. Giuliani L, Favalli C, Syrjanen K, Ciotti M. Human papillomavirus infections in lung cancer.
318 Detection of E6 and E7 transcripts and review of the literature. *Anticancer Res*. 2007;27: 2697-2704.
- 319 28. Bodaghi S. Colorectal Papillomavirus Infection in Patients with Colorectal Cancer. *Clinical Cancer*

- 320 Research. 2005;11: 2862-2867.
- 321 29. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE. High-risk human
322 papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a
323 tissue microarray study. *Br. J. Cancer.* 2008;99: 404-407.
- 324 30. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K. Detection of human
325 papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina.
326 *BMC Urology.* 2005;5.
- 327 31. Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SH, Kazemi B. Correlation between human
328 papillomavirus infection and bladder transitional cell carcinoma. *BMC Infectious Diseases.* 2005;5.
- 329 32. Vineis P, Alavanja M, Buffler P, et al. Tobacco and Cancer: Recent Epidemiological Evidence. *JNCI*
330 *Journal of the National Cancer Institute.* 2004;96: 99-106.
- 331 33. Boffetta P, Hashibe M. Alcohol and cancer. *Lancet Oncol.* 2006;7: 149-156.
- 332 34. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the
333 role of polymorphisms in candidate genes. *JAMA.* 2008;299: 2423-2436.
- 334 35. Neumann F, Jégu J, Mougin C, et al. Risk of second primary cancer after a first potentially-human
335 papillomavirus-related cancer: A population-based study. *Preventive Medicine.* 2016;90: 52-58.
- 336 36. Tseng C-J, Pao CC, Lin J-D, Soong Y-K, Hong J-H, Hsueh S. Detection of Human Papillomavirus
337 Types 16 and 18 mRNA in Peripheral Blood of Advanced Cervical Cancer Patients and Its Association
338 With Prognosis. *Journal of Clinical Oncology.* 1999;17: 1391-1391.
- 339 37. Liu VW, Tsang P, Yip A, Ng TY, Wong LC, Ngan HY. Low incidence of HPV DNA in sera of
340 pretreatment cervical cancer patients. *Gynecol. Oncol.* 2001;82: 269-272.
- 341 38. Nicol AF, de Andrade CV, Russomano FB, et al. HPV vaccines: their pathology-based discovery,

- 342 benefits, and adverse effects. *Ann. Diagn. Pathol.* 2015;19: 418-422.
- 343 39. Xiong W-M, Xu Q-P, Li X, Xiao R-D, Cai L, He F. The association between human papillomavirus
344 infection and lung cancer: a system review and meta-analysis. *Oncotarget.* 2017;8: 96419-96432.
- 345 40. Khanal A, Lashari BH, Kruthiventi S, et al. The risk of second primary malignancy in patients with
346 stage Ia non-small cell lung cancer: a U.S. population-based study. *Acta Oncologica.* 2018;57:
347 239-243.
- 348 41. Shah BK, Khanal A, Hewett Y. Second Primary Malignancies in Adults with Gastric Cancer - A US
349 Population-Based Study. *Front. Oncol.* 2016;6: 82.
- 350 42. Lee JS, DuBois SG, John Boscardin W, Wustrack RL, Goldsby RE. Secondary malignant
351 neoplasms among children, adolescents, and young adults with osteosarcoma. *Cancer.* 2014;120:
352 3987-3993.
- 353 43. Kamp K, Damhuis RAM, Feelders RA, de Herder WW. Occurrence of second primary malignancies
354 in patients with neuroendocrine tumors of the digestive tract and pancreas. *Endocrine-Related Cancer.*
355 2012;19: 95-99.
- 356 44. Suk R, Mahale P, Sonawane K, et al. Trends in Risks for Second Primary Cancers Associated With
357 Index Human Papillomavirus–Associated Cancers. *JAMA Network Open.* 2018;1: e181999.
- 358 45. Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and Early Detection of Cervical
359 Cancer. *Oncol Res Treat.* 2016;39: 501-506.
- 360 46. Leeds IL. Anal cancer and intraepithelial neoplasia screening: A review. *World Journal of*
361 *Gastrointestinal Surgery.* 2016;8: 41.

362

Table 1. SIRs of all site after the diagnosis of HPV-related cancer (initial primary sites shown)

| Initial Primary Site | Male | | Female | |
|-------------------------|----------|-------------------------------|----------|-------------------------------|
| | Observed | SIR(95%CI) | Observed | SIR(95%CI) |
| HPV-Related Sites | 3,463 | 1.60 [#] (1.55-1.65) | 7,372 | 1.25 [#] (1.22-1.28) |
| HPV-related Oral Cancer | 2,531 | 1.85 [#] (1.78-1.92) | 911 | 2.25 [#] (2.11-2.40) |
| Vulva | NA | NA | 1,273 | 1.41 [#] (1.34-1.49) |
| Vagina | NA | NA | 224 | 1.29 [#] (1.13-1.47) |
| Anus | 454 | 1.22 [#] (1.11-1.33) | 650 | 1.31 [#] (1.21-1.42) |
| Penis | 478 | 1.13 [#] (1.03-1.24) | NA | NA |
| Cervix Uteri | NA | NA | 4,314 | 1.10 [#] (1.07-1.13) |

Confidence intervals are 95%.

[#] P<0.05.

* Confidence interval.

Table 2. Hazard model of probabilities of SPM after initial primary HPV-related cancer

| Characteristic | SPM of Male | | SPM of Female | |
|-----------------------|--------------------|---------|--------------------|---------|
| | sdHR# (95% CI') | p-value | sdHR# (95% CI') | p-value |
| Age | | | | |
| 18-65 years | Reference | | | |
| 65+ years | 1.08 (0.92 - 1.27) | 0.360 | 1.50 (1.28 - 1.76) | <0.001 |
| Race | | | | |
| White | Reference | | | |
| Black | 1.04 (0.82 - 1.32) | 0.730 | 1.08 (0.87 - 1.34) | 0.470 |
| Other/Unknown | 0.74 (0.51 - 1.09) | 0.130 | 0.92 (0.72 - 1.17) | 0.480 |
| Marital Status | | | | |
| Married | Reference | | | |
| Unknown | 0.77 (0.54 - 1.10) | 0.150 | 0.88 (0.66 - 1.17) | 0.390 |
| Unmarried | 0.74 (0.63 - 0.86) | <0.001 | 0.77 (0.66 - 0.90) | <0.001 |
| TNM stage | | | | |
| I | Reference | | | |
| II | 0.74 (0.56 - 1.00) | 0.049 | 1.11 (0.90 - 1.36) | 0.320 |
| III | 0.87 (0.67 - 1.15) | 0.330 | 0.84 (0.67 - 1.05) | 0.120 |
| IV | 0.67 (0.53 - 0.85) | 0.001 | 0.66 (0.50 - 0.86) | 0.002 |
| Unknown | 0.67 (0.50 - 0.91) | 0.009 | 1.10 (0.88 - 1.37) | 0.420 |
| Surgery | | | | |
| Surgery Performed | Reference | | | |
| Surgery not Performed | 0.97 (0.83 - 1.13) | 0.660 | 0.73 (0.62 - 0.86) | <0.001 |

| | | | | |
|---------|--------------------|-------|--------------------|-------|
| Unknown | 0.98 (0.46 - 2.11) | 0.960 | 0.14 (0.03 - 0.55) | 0.005 |
|---------|--------------------|-------|--------------------|-------|

sdHR: subdistribution hazard ratio; * CI: confidence interval.


Figure legends

Figure 1. SIRs after the diagnosis of the initial primary HPV-related cancer


Figure 2. SIRs after the diagnosis of the initial primary HPV-unrelated cancer

Figure 3. SIRs after the diagnosis of the initial primary HPV-related cancer by attained calendar year

Female




Male



medRxiv preprint doi: <https://doi.org/10.1101/2020.01.29.19004507>; this version posted January 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


Female

| SPM Site | Observed Cases | SIR |
|---|----------------|-------------|
| All Sites | 158,188 | 1.12 |
| All Solid Tumors | 141,983 | 1.13 |
| HPV-Related Cancer | 2,969 | 0.87 |
| HPV-Unrelated Cancer | 155,219 | 1.12 |
| Oral Cavity and pharynx | 3,352 | 1.44 |
| Oral Cancer | 2,182 | 1.44 |
| Tonsil | 236 | 1.22 |
| Oropharynx | 77 | 1.29 |
| Female Genital System | 14,727 | 0.92 |
| Cervix Uteri | 979 | 0.68 |
| Ovary | 4,093 | 0.92 |
| Vagina | 361 | 1.36 |
| Vulva | 804 | 0.88 |
| Respiratory System | 23,785 | 1.16 |
| Nose, Nasal Cavity and Middle Ear | 232 | 1.25 |
| Larynx | 528 | 1.12 |
| Lung and Bronchus | 22,952 | 1.15 |
| Trachea | 38 | 2.10 |
| Digestive System | 31,178 | 1.03 |
| Esophagus | 1,088 | 1.28 |
| Stomach | 2,382 | 1.08 |
| Colon and Rectum | 19,121 | 1.04 |
| Colon excluding Rectum | 15,029 | 1.05 |
| Rectum and Rectosigmoid Junction | 4,092 | 1.00 |
| Anus, Anal Canal and Anorectum | 512 | 0.95 |
| Liver | 833 | 0.86 |
| Pancreas | 4,489 | 0.97 |
| Breast | 48,813 | 1.23 |
| Urinary System | 8,795 | 1.18 |
| Urinary Bladder | 5,080 | 1.23 |
| Kidney | 2,917 | 1.06 |
| Brain | 1,267 | 0.94 |
| Thyroid | 2,658 | 1.22 |
| All Lymphatic and Hematopoietic Diseases | 12,627 | 1.06 |
| Lymphoma | 6,453 | 1.04 |
| Leukemia | 4,388 | 1.17 |
| Skin excluding Basal and Squamous | 6,152 | 1.39 |
| Melanoma of the Skin | 5,498 | 1.39 |



Male

| SPM Site | Observed Cases | SIR |
|---|----------------|-------------|
| All Sites | 186,579 | 0.88 |
| All Solid Tumors | 162,514 | 0.87 |
| HPV-Related Cancer | 1,744 | 1.15 |
| HPV-Unrelated Cancer | 184,835 | 0.88 |
| Oral Cavity and pharynx | 6,930 | 1.28 |
| Oral Cancer | 4,118 | 1.29 |
| Tonsil | 728 | 1.16 |
| Oropharynx | 217 | 1.19 |
| Male Genital System | 31,536 | 0.49 |
| Prostate | 30,535 | 0.48 |
| Penis | 316 | 0.94 |
| Respiratory System | 38,812 | 1.07 |
| Nose, Nasal Cavity and Middle Ear | 373 | 1.27 |
| Larynx | 2,652 | 1.08 |
| Lung and Bronchus | 35,665 | 1.07 |
| Trachea | 73 | 2.25 |
| Digestive System | 41,915 | 0.98 |
| Esophagus | 3,321 | 1.10 |
| Stomach | 4,480 | 0.97 |
| Colon and Rectum | 22,678 | 0.96 |
| Colon excluding Rectum | 16,488 | 0.97 |
| Rectum and Rectosigmoid Junction | 6,190 | 0.95 |
| Anus, Anal Canal and Anorectum | 483 | 1.31 |
| Liver | 2,232 | 0.81 |
| Pancreas | 5,539 | 0.97 |
| Breast | 512 | 1.13 |
| Urinary System | 26,193 | 1.11 |
| Urinary Bladder | 18,042 | 1.08 |
| Kidney | 6,127 | 1.09 |
| Brain | 1,854 | 0.98 |
| Thyroid | 1,416 | 1.35 |
| All Lymphatic and Hematopoietic Diseases | 19,162 | 1.04 |
| Lymphoma | 9,561 | 1.11 |
| Leukemia | 6,565 | 1.00 |
| Skin excluding Basal and Squamous | 11,253 | 1.24 |
| Melanoma of the Skin | 10,093 | 1.25 |



medRxiv preprint doi: <https://doi.org/10.1101/2020.01.29.19004507>; this version posted January 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

